ELVN
HEALTHCAREEnliven Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving ELVN Today?
No stock-specific AI insight has been generated for ELVN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$41.20
Fundamentals
Trading
ELVN News
20 articles- Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateYahoo Finance·May 7, 2026
- Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML MarketYahoo Finance·Apr 17, 2026
- Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and MizuhoYahoo Finance·Apr 6, 2026
- Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price MomentumYahoo Finance·Mar 30, 2026
- Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 MillionMotley Fool·Mar 28, 2026
- Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’Yahoo Finance·Mar 26, 2026
- Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateYahoo Finance·Mar 3, 2026
- Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 25, 2026
- Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500kMotley Fool·Feb 1, 2026
- Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging Phase 1b ENABLE Trial DataYahoo Finance·Jan 9, 2026
- Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical MilestonesYahoo Finance·Jan 8, 2026
- Enliven Therapeutics Bolsters Board to Prepare for Next Phase of DevelopmentYahoo Finance·Jan 7, 2026
- Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing RulesYahoo Finance·Dec 11, 2025
- Enliven Therapeutics Announces New CEO to Drive Next Phase of DevelopmentYahoo Finance·Dec 11, 2025
- Enliven Therapeutics (ELVN): Evaluating Valuation After a Recent Share Price Rebound and Ongoing Clinical ProgressYahoo Finance·Dec 9, 2025
- Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to TradeYahoo Finance·Dec 3, 2025
- Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect?Yahoo Finance·Nov 17, 2025
- /C O R R E C T I O N -- Enliven Therapeutics, Inc./Yahoo Finance·Nov 13, 2025
- Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual MeetingYahoo Finance·Nov 3, 2025
- Assessing Enliven Therapeutics (ELVN) Valuation as Shares Show Signs of Short-Term MomentumYahoo Finance·Oct 24, 2025
All 20 articles loaded
Price Data
52-Week Range
$41.20
Fundamentals
Trading
About Enliven Therapeutics Inc
Enliven Therapeutics Inc. (Ticker: ELVN) is a pioneering biotechnology firm dedicated to revolutionizing cancer therapy and tackling other critical illnesses through its proprietary therapeutic platforms. The company boasts a robust pipeline of innovative drug candidates developed via advanced biopharmaceutical technologies aimed at improving patient outcomes and enhancing quality of life. With a strong emphasis on scientific innovation and a commitment to addressing significant unmet medical needs in oncology, Enliven is well-positioned to drive shareholder value and make meaningful contributions to the healthcare ecosystem.